Chinese Natural Remedy For Coronary Heart Disease Attracts MNC Interest
This article was originally published in PharmAsia News
Executive Summary
The regenerative medicine laboratory jointly set up by the Chinese University of Hong Kong and Jinan University of Guangdong recently developed a natural remedy for treating coronary heart disease. Researchers say that the natural remedy, based on an edible Chinese herbal medicine usually consumed for headaches and urinary problems, has been tested on patients with coronary occlusion and late-stage coronary heart disease. Trial results show excellent therapeutic effects in the subjects from China, Hong Kong, Canada and the U.S. The lab plans to use the two active components extracted to develop five drugs, which are expected to launch in three years. Sources disclose that the remedy, whose intellectual property has been purchased by a Hong Kong businessman, is attracting the attention of many pharmaceutical MNCs. (Click here for more - Chinese Language)
You may also be interested in...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.